skip to Main Content

Leadership

Allen Baharaff
President & Chief Executive Officer

Mr. Baharaff is the co-​founder of Galmed Pharmaceuticals Ltd., and has served as CEO since 2012, and President as of 2015. He holds a Bachelor of Science degree from the University of London (LSE) and LLB and MA degrees from Cambridge University. Mr. Baharaff has held a number of direc­tor­ships including a SVP position at Isramex Projects Ltd., and T+M Trusteeship & Management. He also serves as a Director of the Tel-​Aviv Museum of Arts and Executive Director at The Rubin Museum.

Liat Hayardeny, Ph.D.
Chief Scientific Officer

Dr. Hayardeny joined Galmed in 2016 bringing more than 16 years of experience in drug devel­opment as part of Teva Pharmaceuticals’ global R&D Division. Prior to joining Galmed, Dr. Hayardeny served as Teva’s Senior Director and Head of Research Scientific Affairs. In that capacity, Dr. Hayardeny estab­lished the scien­tific positioning of Teva’s innov­ative compounds. Additionally, Dr. Hayardeny was respon­sible for the company’s relationship with insti­tu­tions of higher education; managing Teva’s global research collab­o­ra­tions and publi­ca­tions. Dr. Hayardeny holds a Ph.D. from Sackler School of Medicine and an MBA from Recanati Business School at Tel Aviv University.

Yohai Stenzler
Chief Financial Officer

Mr. Stenzler joined Galmed in 2014 and has served as Galmed’s Chief Financial Officer since February 2017. Prior to joining Galmed, Mr. Stenzler was an accountant at Ernst & Young LLP, where he was involved in financing, taxes, auditing, advising and accounting of public and private companies, both domestic and inter­na­tional. Mr. Stenzler is a certified CPA and holds an MBA in Finance from Recanati Business School at Tel Aviv University, and a BA in Economics and Accounting from Ben-​Gurion University.

Tali Gorfine, M.D.
Chief Medical Officer

Dr. Gorfine joined Galmed 2016. Prior to joining Galmed, she served as a Senior Clinical Program Leader at Teva R&D. In that capacity, she led product strategy and clinical devel­opment in the field of multiple sclerosis and was respon­sible for large Phase II and III studies. Dr. Gorfine holds an MD., and a PhD in the field of functional magnetic resonance imaging (fMRI) from the Tel-​Aviv University.

Guy Nehemya
Vice President, Operations

Mr. Nehemya joined Galmed in 2013 as Galmed’s Director of Operations and has served as the Company’s Vice President, Operations since March 2017. Mr. Nehemya was a key member of management during the Company’s IPO. Mr. Nehemya holds an MBA from Arison School of Business at IDC Herzliya and an LL.B. from the College of Management. Mr. Nehemya has been a member of the Israeli Bar Association since 2012.

Joseph Kaspi Ph.D.
Senior CMC Director

Dr. Kaspi joined Galmed in December 2016 bringing with him rich experience of more than 35 years in process devel­opment of pharma­ceu­tical active ingre­dients (API). Dr. Kaspi held positions of VP for R&D and Chief Scientific Officer in Perrigo API (formerly Chemagis). Earlier he served as process devel­opment leader in the chemical section of Teva R&D. A Ph.D. degree in organic chemistry from the Hebrew University in Jerusalem is held by him.

Yael Hollander
Vice President, Legal Affairs and Strategy

Ms. Hollander joined Galmed in 2014 and has served as the Company’s Vice President, Legal Affairs and Strategy since March 2017. She has extensive experience as a commercial lawyer at Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co. law offices, where she was involved in the repre­sen­tation of both publicly-​traded and private companies in connection with corporate finance, public offerings, mergers and acqui­si­tions, commercial trans­ac­tions, corporate gover­nance, and other securities, legal and business issues. Ms. Hollander holds an MBA in Finance from Recanati Business School at Tel Aviv University, and an LL.B. and BA in Economics from the Hebrew University of Jerusalem. Ms. Hollander has been a member of the Israeli Bar Association since 2010.

Back To Top